Pneumococcal conjugate vaccines (PCV) have reduced invasive pneumococcal disease (IPD) (see other PSERENADE abstract), of which > 70% was vaccine-type pre-PCV. We described the serotype (ST) distribution of remaining IPD in countries with mature infant PCV10/13 programs. METHODS. IPD ST ...
Year of PCV7 introduction (vaccine schedule†) 2009 (3 + 1, with catch-up) 2009 (2 + 1, with catch-up) No PCV7 introduction 2009 (2 + 1, without catch-up) 2009 (3 + 0, without catch-up) 2000 (3 + 1, with catch-up) Year of PCV10 or PCV13 introd...
series;(4)“catch-up”immunizationforchildrenbehindschedule;and (5)PCV13forcertainchildrenathighriskfrom6through18yearsof age.Inaddition,recommendationsfortheuseofpneumococcalpoly- saccharidevaccineforchildrenathighriskofIPDarealsoupdated. Pediatrics2010;126:000 ...
Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake. Vaccine 2013; 31: 5983-88.Schuck-Paim C, Taylor R, Lindley D, Klugman KP, Simonsen L. Use of near-real-time medical claims data to generate timely...
Private market use of PCV uses a different schedule (3 + 1) than the NIP (2 + 1). To date, PCV10 has been chosen for the NIP and private market PCV13 use is approximately 30%. 12 Range of vaccine uptake is 49–60%. 13 Australia (non-indigenous) switched from 3 + 0 to 2 +...